PR Newswire10.14.16
BTG plc, an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit90Y dosimetry software, designed to optimize the planning of 90Y selective internal radiation therapy (SIRT) and facilitate personalized treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit90Y in Canada.
BTG, in collaboration with Mirada Medical, have developed Simplicit90Y to be a customized, easy-to-use, dosimetry software developed for rapid 90Y SIRT workflow. Simplicit90Y provides digital processing, review, and reporting of medical images with unique options for data display, quality control, image manipulation, and quantification analysis. Together, these features allow for more standardized and consistent dosimetry planning and post-treatment validation, and the ability to personalize treatment for each patient.
"Simplicit90Y represents an important advance in providing patients and healthcare providers with added value beyond our products and we are pleased it has received CE Mark certification," commented Zillah Moore, Director Commercial Operations EMEA. "It will ensure 90Y therapies, such as TheraSphere, can be specifically tailored to individual patient needs, facilitating personalized treatments. Simplicit90Y will help us offer interventional oncology teams more power to personalize and optimize 90Y SIRT for their patients. We're delighted Simplicit90Y is now available for physicians to use."
"Dosimetry can be a time intensive and complex process and Simplicit90Y simplifies both dosimetry planning and post-treatment validation," said Etienne Garin, MD, PhD, Chair professor of Nuclear Medicine, Cancer Institute, Centre Eugene Marquis Rennes, France. "Knowing you can use this intuitive software to help deliver a more personalized treatment for each patient, achieving the best dose of 90Y radiation to the tumor while minimizing exposure to healthy tissue, gives physicians more confidence."
Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director commented, "We designed this software to simplify the dosimetry workflow for SIRT and enhance consistency and efficiency. Mirada Medical supports 90Y treatment quality by incorporating advanced image processing tools that facilitate the clinician's use of multi-modal images to plan 90Y SIRT treatment. Leveraging combined expertise from across the industry helped meet both the physician's and patient's needs and Simplicit90Y is a clear demonstration of that success."
BTG, in collaboration with Mirada Medical, have developed Simplicit90Y to be a customized, easy-to-use, dosimetry software developed for rapid 90Y SIRT workflow. Simplicit90Y provides digital processing, review, and reporting of medical images with unique options for data display, quality control, image manipulation, and quantification analysis. Together, these features allow for more standardized and consistent dosimetry planning and post-treatment validation, and the ability to personalize treatment for each patient.
"Simplicit90Y represents an important advance in providing patients and healthcare providers with added value beyond our products and we are pleased it has received CE Mark certification," commented Zillah Moore, Director Commercial Operations EMEA. "It will ensure 90Y therapies, such as TheraSphere, can be specifically tailored to individual patient needs, facilitating personalized treatments. Simplicit90Y will help us offer interventional oncology teams more power to personalize and optimize 90Y SIRT for their patients. We're delighted Simplicit90Y is now available for physicians to use."
"Dosimetry can be a time intensive and complex process and Simplicit90Y simplifies both dosimetry planning and post-treatment validation," said Etienne Garin, MD, PhD, Chair professor of Nuclear Medicine, Cancer Institute, Centre Eugene Marquis Rennes, France. "Knowing you can use this intuitive software to help deliver a more personalized treatment for each patient, achieving the best dose of 90Y radiation to the tumor while minimizing exposure to healthy tissue, gives physicians more confidence."
Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director commented, "We designed this software to simplify the dosimetry workflow for SIRT and enhance consistency and efficiency. Mirada Medical supports 90Y treatment quality by incorporating advanced image processing tools that facilitate the clinician's use of multi-modal images to plan 90Y SIRT treatment. Leveraging combined expertise from across the industry helped meet both the physician's and patient's needs and Simplicit90Y is a clear demonstration of that success."